George Jones

George M. Jones is a clinical epidemiologist whose recent work applies large, nationally representative survey datasets to questions at the intersection of psychedelics, addiction and mental health. Using cross-sectional population data, he has led and contributed to multiple papers examining associations between lifetime or recent use of classic psychedelics and a range of outcomes including nicotine dependence, opioid use disorder, cocaine use disorder, impairments in social functioning, and major depressive episodes. His approach emphasises rigorous survey-based methods, control for demographic and psychiatric covariates, and careful interpretation of associations in contexts where causality cannot be inferred.

Jones's contributions have helped characterise possible protective associations between certain psychedelic compounds (including MDMA and psilocybin) and reduced odds of depressive episodes or substance use disorders in community samples, and have advanced discussion about the population-level implications of psychedelic use. His work is situated within addiction epidemiology and public mental health, informing both clinical researchers and policymakers interested in the potential public-health impacts of psychedelic substances.